title: A population pharmacodynamic model for lactate dehydrogenase and neuron specific enolase to predict tumor progression in small cell lung cancer patients.
abstract: The development of individualized therapies poses a major challenge in oncology. Significant hurdles to overcome include better disease monitoring and early prediction of clinical outcome. Current clinical practice consists of using Response Evaluation Criteria in Solid Tumors (RECIST) to categorize response to treatment. However, the utility of RECIST is restricted due to limitations on the frequency of measurement and its categorical rather than continuous nature. We propose a population modeling framework that relates circulating biomarkers in plasma, easily obtained from patients, to tumor progression levels assessed by imaging scans (i.e., RECIST categories). We successfully applied this framework to data regarding lactate dehydrogenase (LDH) and neuron specific enolase (NSE) concentrations in patients diagnosed with small cell lung cancer (SCLC). LDH and NSE have been proposed as independent prognostic factors for SCLC. However, their prognostic and predictive value has not been demonstrated in the context of standard clinical practice. Our model incorporates an underlying latent variable ("disease level") representing (unobserved) tumor size dynamics, which is assumed to drive biomarker production and to be influenced by exposure to treatment; these assumptions are in agreement with the known physiology of SCLC and these biomarkers. Our model predictions of unobserved disease level are strongly correlated with disease progression measured by RECIST criteria. In conclusion, the proposed framework enables prediction of treatment outcome based on circulating biomarkers and therefore can be a powerful tool to help clinicians monitor disease in SCLC.
authors.affiliation: Department of Pharmacy and Pharmaceutical Technology, School of Pharmacy, University of Navarra, Pamplona, 31009, Spain.
authors.forename: Núria
authors.initials: N
authors.lastname: Buil-Bruna
authors.forename: José-María
authors.initials: JM
authors.lastname: López-Picazo
authors.forename: Marta
authors.initials: M
authors.lastname: Moreno-Jiménez
authors.forename: Salvador
authors.initials: S
authors.lastname: Martín-Algarra
authors.forename: Benjamin
authors.initials: B
authors.lastname: Ribba
authors.forename: Iñaki F
authors.initials: IF
authors.lastname: Trocóniz
mesh_terms: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000032:analysis*; D016190:Carboplatin; D018288:Carcinoma, Small Cell / Q000175:diagnosis* / Q000188:drug therapy; D002945:Cisplatin; D018450:Disease Progression; D018572:Disease-Free Survival; D005047:Etoposide; D006801:Humans; D007770:L-Lactate Dehydrogenase / Q000032:analysis*; D008175:Lung Neoplasms / Q000175:diagnosis* / Q000188:drug therapy; D008954:Models, Biological; D010751:Phosphopyruvate Hydratase / Q000032:analysis*; D011153:Population; D011237:Predictive Value of Tests
chemical_list: D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D014408:Biomarkers, Tumor; D005047:Etoposide; D016190:Carboplatin; D007770:L-Lactate Dehydrogenase; D010751:Phosphopyruvate Hydratase; D002945:Cisplatin
references.citation: Cancer Res. 1986 Aug;46(8):4189-94
references.pmid: 3015384
references.citation: JAMA. 2006 Mar 1;295(9):1003-10
references.pmid: 16507801
references.citation: Science. 2009 May 22;324(5930):1029-33
references.pmid: 19460998
references.citation: Clin Cancer Res. 2008 Dec 1;14(23):7813-21
references.pmid: 19047109
references.citation: J Pharmacokinet Pharmacodyn. 2007 Feb;34(1):57-85
references.pmid: 17051439
references.citation: Clin Cancer Res. 2013 May 15;19(10):2629-36
references.pmid: 23669423
references.citation: Blood. 1989 Dec;74(8):2644-51
references.pmid: 2479425
references.citation: J Clin Oncol. 2004 Nov 15;22(22):4442-5
references.pmid: 15483011
references.citation: Cancer. 1998 Mar 15;82(6):1049-55
references.pmid: 9506348
references.citation: Annu Rev Pharmacol Toxicol. 2001;41:347-66
references.pmid: 11264461
references.citation: Pharm Res. 2005 Sep;22(9):1432-7
references.pmid: 16132354
references.citation: Eur J Cancer. 2009 Jan;45(2):228-47
references.pmid: 19097774
references.citation: Nat Rev Cancer. 2002 Sep;2(9):683-93
references.pmid: 12209157
references.citation: Lung Cancer. 2000 Oct;30(1):51-3
references.pmid: 11008009
references.citation: Ann Oncol. 2014 Jan;25(1):41-56
references.pmid: 24356619
references.citation: Lung Cancer. 2000 Jun;28(3):173-85
references.pmid: 10812187
references.citation: Lung Cancer. 2000 Nov;30(2):127-34
references.pmid: 11086206
references.citation: Comput Methods Programs Biomed. 2005 Sep;79(3):241-57
references.pmid: 16023764
references.citation: Mod Pathol. 2010 Jan;23(1):45-53
references.pmid: 19838163
references.citation: Lung Cancer. 2008 Nov;62(2):261-72
references.pmid: 18442869
references.citation: Cancer Res. 2012 May 1;72(9):2218-27
references.pmid: 22422938
references.citation: J Proteome Res. 2012 Feb 3;11(2):554-63
references.pmid: 22050456
references.citation: Br J Cancer. 1999 Feb;79(3-4):515-9
references.pmid: 10027322
references.citation: Blood. 1996 Oct 15;88(8):2819-25
references.pmid: 8874177
references.citation: Biometrics. 1990 Sep;46(3):673-87
references.pmid: 2242409
references.citation: J Clin Oncol. 1999 Jan;17(1):409-22
references.pmid: 10458260
references.citation: Respiration. 1997;64(1):102-7
references.pmid: 9044484
references.citation: Expert Opin Investig Drugs. 2008 Oct;17(10):1533-45
references.pmid: 18808312
references.citation: Clin Chem. 1993 Apr;39(4):561-77
references.pmid: 8472349
references.citation: Transfusion. 1996 Jul;36(7):590-5
references.pmid: 8701453
references.citation: AAPS J. 2011 Jun;13(2):143-51
references.pmid: 21302010
references.citation: Anticancer Res. 2008 Sep-Oct;28(5B):3027-33
references.pmid: 19031951
references.citation: AAPS J. 2009 Sep;11(3):558-69
references.pmid: 19649712
references.citation: Cancer Chemother Rep 3. 1973 Mar;4(2):31-42
references.pmid: 4580860
references.citation: Br J Clin Pharmacol. 2015 Jan;79(1):56-71
references.pmid: 24134068
references.citation: Lung Cancer. 2012 Jun;76(3):263-8
references.pmid: 22177533
references.citation: J Pharmacokinet Biopharm. 1995 Feb;23(1):5-8; discussion 9-10
references.pmid: 8576844
references.citation: Cancer. 1981 Nov 15;48(10):2274-8
references.pmid: 6170417
references.citation: J Pharmacol Exp Ther. 2012 Sep;342(3):788-98
references.pmid: 22691297
references.citation: Br J Cancer. 1988 Dec;58(6):805-7
references.pmid: 2852029
references.citation: Br J Cancer. 1996 Aug;74(3):463-7
references.pmid: 8695366
references.citation: Clin Biochem. 2004 Jul;37(7):505-11
references.pmid: 15234231
references.citation: Drugs. 2000;59 Suppl 4:9-17; discussion 37-8
references.pmid: 10864226
references.citation: PLoS One. 2012;7(3):e32653
references.pmid: 22461886
references.citation: Science. 1956 Feb 24;123(3191):309-14
references.pmid: 13298683